Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a research note issued on Sunday. They presently have a $200.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 44.73% from the stock’s previous close.
The analysts wrote, “Cantor Fitzgerald will host a physician conference call on Tuesday to provide perspective on pitolisant as it relates to JAZZ’s sleep franchise. The call is at 1:00pm EST and the dial in number can be obtained from your Cantor sales rep. Note that the call will be 30 minutes in duration. Questions for the consultant can be emailed to [email protected]””
Several other equities analysts have also recently commented on the stock. UBS dropped their target price on shares of Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. Janney Montgomery Scott restated a “buy” rating and issued a $192.00 target price (up from $180.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. Morgan Stanley initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price for the company. Deutsche Bank set a $175.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Cowen restated an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $180.25.
In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the sale, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total transaction of $46,882.88. Following the sale, the director now directly owns 1,365 shares in the company, valued at $181,804.35. The disclosure for this sale can be found here. Insiders have sold a total of 10,352 shares of company stock worth $1,417,763 over the last three months. Insiders own 4.30% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. Toronto Dominion Bank grew its holdings in Jazz Pharmaceuticals by 12.4% during the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after acquiring an additional 81 shares during the last quarter. US Bancorp DE boosted its stake in shares of Jazz Pharmaceuticals by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares during the last quarter. Gargoyle Investment Advisor L.L.C. bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $206,000. Advisor Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 550 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $211,000. 91.28% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/jazz-pharmaceuticals-jazz-buy-rating-reiterated-at-cantor-fitzgerald.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.